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Summary The expression of p53 protein, oestrogen receptor protein, epidermal growth factor receptor
(EGFR) and overexpression of the c-erbB-2 oncoprotein was examined in a series of 149 primary symptomatic
breast carcinomas. Expression of p53 was present in 62 of 146 cases (42.5%) of the invasive carcinoma and
one of three cases (33.3%) of ductal carcinoma in situ (DCIS) examined. Statistical associations of tumour
oestrogen receptor positivity and lack of p53 protein expression, x2 = 19.78 (d.f. = 1), P<0.001, positive
tumour p53 status and poor tumour grade; X2 = 14.1 (d.f. = 2), P<0.001, EGFR expression X= 7.07,
(d.f. = 1), P<0.01 and tumour c-erbB-2 protein overexpression; x2 = 4.61 (d.f. = 1), P = 0.032 were identified.
Expression of p53 is rare in invasive lobular carcinoma of classical type (8.3% of cases examined) in contrast
to other common types of mammary carcinoma. Non-significant trends of p53 protein expression and
increased regional tumour recurrence; x2 = 3.20 (d.f. = 1), P = 0.074 and also poorer patient survival; x2 = 3.76
(d.f. = 1), P = 0.053 were identified. p53 protein expression is a common event in human breast cancer and is
present in both DCIS and invasive mammary carcinoma. Abnormal expression of p53 protein is a feature of
both in situ and invasive breast carcinoma, implying that the abnormal p53 protein expression may be
implicated in the early stages of mammary carcinoma progression.
The human p53 gene protein is a nuclear phosphoprotein
with a nuclear targeting sequence which directs p53 to the
cell nucleus (Dang & Lee, 1989). p53 protein was originally
identified in extracts of transformed cells reacting with anti-
serum from animals innoculated with tumour cell lines trans-
formed by simian virus 40 (SV 40) (Lane & Crawford, 1979;
Linzer & Levine, 1979). The p53 protein was also identified
in chemically and retrovirus transformed cells where the
protein is expressed at high levels due to protein stabilisation
(Linzer & Levine, 1979; Melero et al., 1980). The p53 gene is
now thought to be a tumour suppressor gene, negatively
regulating the cell cycle via the p53 gene protein and requir-
ing loss of function mutations for tumour formation (Milner
& Watson, 1991). p53 gene mutation appears to be the most
common gene mutation identified in carcinomas to date
(Harris, 1991) with mutations of the p53 gene commonly
seen in primary breast, colonic, ovarian, lung and oeso-
phageal carcinomas (Hollstein et al., 1991). The abnormal
protein coded for by various p53 gene mutants (mutant p53
protein) is more stable and therefore has a much longer half
life than the normal or 'wild type' p53 gene protein (Finlay et
al., 1988). This inherent stability allows detection of mutant
p53 proteins using immunohistochemistry, the wild type
being much harder to detect (Iggo et al., 1990). There is now
evidence that p53 mutation may not be the only mechanism
implicated in expression of the p53 protein at the immunohis-
tochemical level, and that altered or abnormal p53 degrada-
tion may also in certain situations be important in the
immunocytochemical detection of p53 protein (Wynford-
Thomas, 1992). 'Wild-type' p53 protein is also detectable by
immunohistochemistry in certain ras transformed rat thyroid
cell lines (Wynford-Thomas, 1992). The p53 gene is located
on human chromosome 17pl3 (Isobe et al., 1986), and par-
tial or complete loss of one allele on chromsome 17p is
frequently seen in human breast carcinoma (Mackay et al.,
1988).
The mechanism of wild type p53 function in normal cells is
unknown, however in cells transfected with the wild type p53
gene, the wild type p53 protein may be able to activate gene
transcription while the mutant p53 protein appears unable to
activate transcription (Raycroft et al., 1991). It has recently
been suggested that the cell growth response involves a
switch from a suppressor to a promoter conformational
change in the p53 protein (Milner & Watson, 1990). Com-
plete absence of p53 protein in mice homozygous for a null
mutant p53 allele has been recently shown to be compatible
with embryonic development and survival of null mutant p53
mice to maturity (Donehower et al., 1992).
A small number of previous studies have examined p53
protein expression in human mammary carcinoma utilising
immunohistochemistry, showing p53 protein expression to be
present in 27-54% of primary breast carcinomas (Bartek et
al., 1990a; Cattoretti et al., 1988a, b; Davidoff et al., 1991b;
Horak et al., 1991; Ostrowski et al., 1991; Walker et al.,
1991). Immunohistochemical expression of p53 protein is
seen in neoplastic breast tissue but not in normal breast
tissue and infrequently in atypical hyperplasias of the breast
(Bartek et al., 1990a).
Expression of the epidermal growth factor receptor (EGFR)
and overexpression of the related oncogene protein c-erbB-2
have also been shown to be adverse prognostic factors in
mammary carcinoma (Sainsbury et al., 1987; Slamon et al.,
1989; Lovekin et al., 1991). A statistically significant associa-
tion between p53 protein expression and expression of EGFR
in breast carcinoma has been reported in one series (Catto-
retti et al., 1988a) although no significant association of p53
protein expression and expression of c-erbB-2 in breast car-
cinoma was noted in two other published series (Davidoff et
al., 1991b; Walker et al., 1991).
Our aim in this study was to examine the relationship of
p53 protein expression, pathological tumour variables and
patient survival in a well documented series of primary breast
carcinomas. We also wished to examine the relationship of
p53 protein expression, oestrogen receptor, EGFR and c-
erbB-2 protein expression in breast carcinoma and so to
establish the relationship between the three latter well estab-
lished prognostic factors and expression of p53; a novel
tumour suppressor protein. As p53 gene mutations are
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thought to be a common event in breast cancer, then
immunohistochemical expression of the p53 gene protein
might also be an independent prognostic factor in human
mammary carcinoma.
Materials and methods
Antibodies
pAbl801 is a mouse monoclonal anti-p53 antibody (Euro-
Path Ltd, Bude, Cornwall, UK) which recognises an epitope
near the N-terminus of both the wild and mutant forms of
the human p53 protein (Banks et al., 1986). EGFR-1, a
mouse monoclonal anti-epidermal growth factor receptor
antibody (Amersham Ltd, Amersham, UK) was utilised to
examine expression of EGFR. Examination of overexpres-
sion of the c-erbB-2 protein was performed using the poly-
clonal rabbit antibody 21N (Venter et al., 1987), a generous
gift of Dr W.J. Gullick, ICRF Molecular Oncology Group,
London.
Patients and tissues
One hundred and forty-six invasive carcinomas and three
cases of ductal carcinoma in situ (DCIS) drawn from the
Nottingham/Tenovus Primary Breast Carcinoma Series
(Todd et al., 1987) were examined. All the patients were
under the care of one surgical team (Professor R.W. Blamey).
A wide variety of clinical and pathological data is available
on this series, including tumour type, size, stage, nodal
status, local recurrence, patient survival, and tumour grade.
The tumours were typed according to the recently propos-
ed criteria of Ellis et al. (1992) and graded using the recently
published criteria of Elston and Ellis (1991). Six ftm thick
frozen sections were cut at -20°C from tissue stored at
- 70C of 149 symptomatic primary breast carcinomas. The
sections were then air-dried at 18°C for approximately 2 h.
For assessment of p53 and c-erbB-2 expression sections
were then fixed in formalin at pH 7.4 for 10min at 18°C.
EGFR expression was assessed after fixation of sections in an
acetone/chloroform mixture at 4°C for 10 min. The results of
tumour immunohistochemistry was examined by C.E.H. and
J.A.B. in all cases and were also evaluated by D.N.P. or
I.O.E. in cases where the results were equivocal and a joint
decision was made. Oestrogen receptor content was measured
at the Tenovus Institute, Cardiff using the dextran coated
charcoal method. A seven point assay was employed and the
results were calculated using Scatchard plots. Tumours with
an oestrogen receptor content greater than 5 fmol mg-' cyto-
solic protein were considered oestrogen receptor positive.
Immunohistochemistry
pAb 1801 primary antibody was used at 1:20 dilution,
EGFR-1 at 1:10 dilution and 21N at 1:150 dilution. After
incubation with the respective primary antibodies at 18°C for
30 min, incubation with a polyclonal biotinylated rabbit anti-
mouse antibody was performed (Dako Ltd, High Wycombe,
UK) in the case of pAb 1801 and EGFR-I and a polyclonal
biotinylated swine anti-rabbit antibody with 21N (Dako Ltd,
High Wycombe, UK), followed by incubation with avidin/
biotin complex conjugated to horseradish peroxidase (Dako
UK Ltd, High Wycombe, UK) then followed by 3,3-
diaminobenzidene as a chromogen. Each section was
incubated in the absence of each of the primary antibodies
(pAb 1801, EGFR-1, and 21N) as a negative control.
Tumours ofknown p53 or EGFR protein expression, or gene
amplification in the case of c-erbB-2 were used as positive
controls in the immunohistochemical examination of p53,
EGFR, and c-erbB-2 protein expression. The sections were
examined by light microscopy. p53 protein expression was
indicated by nuclear staining of tumour cells. Lack of p53
protein expression was indicated by absence of tumour cell
nuclear staining with pAb 1801.
At least 500 carcinoma cell nuclei were counted in each of
six areas of the tumour for assessment of p53 immunore-
activity. Homogenous or heterogeneous tumour membrane
immunoreactivity was utilised to indicate tumour EGFR ex-
pression. Positive tumour cell membrane immunoreactivity
with EGFR-1 had been previously shown to indicate EGFR
expression in a number of control tumours which showed
high level expression of EGFR using an EGFR radio-
immunoassay. Tumour membrane immunoreactivity, either
homogenous or heterogeneous was utilised as the sole
criterion of c-erbB-2 oncoprotein overexpression.
Statistical analysis
Probability of survival curves were calculated for patients in
each category using the life table method, and Mantel's test
was used to assess the difference between the survival curves,
with the chi-squared test for trend. The analysis were per-
formed using standard computer statistics software; BMDPTm
and SPSS_XTM.
Results
p53, EGFR, c-erb-B2 immunohistochemistry and oestrogen
receptor status
p53 With pAb 1801 62 of 146 cases of invasive mammary
carcinoma (42.5%) showed postive p53 immunoreactivity.
p53 immunoreactivity was largely confined to the nuclei of
the carcinoma cells (see Figure 1). No staining of normal
breast ducts, breast acini or surrounding breast stroma was
identified. A few cases only showed very weak diffuse cyto-
plasmic staining of the tumour cells which was not analysed
further. The percentage of tumour cell nuclei staining in
positive cases was variable, ranging from 5-100%. Thirty-
eight of 74 invasive ductal carcinomas of no special type
(51.3%) were p53 positive (see Table I), five of nine car-
cinomas of mixed ductal and lobular type (55.5%) were p53
positive, six of 23 carcinomas of tubular-mixed type (26.1%)
were p53 positive, one of 12 invasive classical lobular car-
cinomas (8.3%) was p53 positive, two of three carcinomas of
lobular-mixed type (66.6%) were p53 positive, 0 of 2 tubular
carcinomas were p53 positive (0%), a single medullary car-
cinoma was p53 positive (100%), and single mucoid car-
cinoma was p53 negative (0%). Of the remaining 11 cases of
invasive mammary carcinoma of other special types five were
p53 positive. Three cases of ductal carcinoma in situ were
examined; one case (33.3%) being p53 positive.
EGFR Forty-eight (32.9%) of the 146 invasive carcinomas
examined showed membrane immunoreactivity with EGFR-1,
indicating EGFR expression. Both membrane and cytoplas-
mic staining of tumour cells was seen with EGFR-1 as well
as staining of the epithelium of normal breast ducts, breast
acini and the myoepithelial cells of surrounding normal
breast ducts. The degree of EGFR staining was variable,
with some tumours showing homogenous tumour immuno-
reactivity and other tumours showing variable degrees of
heterogeneous staining.
Table I Tumour p53 staining with pAb 1801 and tumour type
Tumour type p53 positive p53 negative % p53 positive
Ductal NST 38 36 51
Lobular (classical) 1 11 8.3
Ductal/lobular 5 4 55
Tubular 0 2 0
Tubular/mixed 6 17 26
Lobular mixed 2 1 66
Atypical medullary 6 4 60
Medullary 1 0 100
Mucoid 0 1 0
Other types 5 6 45
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Figure 1 Breast carcinoma nuclei showing intense positive s
magnification.
c-erbB-2 Fifty-eight of 146 (39.7%) of the invasive mam-
mary carcinomas showed positive membrane immunore-
activity with 21N, indicating overexpression of the c-erbB-2
protein. Membrane and cytoplasmic tumour cell immuno-
reactivity was seen with 21N. c-erbB-2 overexpression and
gene amplification had been previously confirmed in a
number of control tumours that showed positive membrane
immunoreactivity with 21N. No c-erbB-2 immunoreactivity
of normal breast ducts, breast acini, or myoepithelial cells
was seen.
Oestrogen receptor Utilising the standard radioimmuno-
assay procedure described above 93 of 134 (69.4%) of inva-
sive carcinomas were considered oestrogen receptor positive.
Of the oestrogen receptor positive invasive carcinomas 26 of
93 (27.9%) showed p53 protein expression as compared to 29
of 41 (70.7%) of the tumours considered oestrogen receptor
negative.
Comparison of the various groups showed no consistent
pattern of p53, oestrogen receptor, EGFR, and c-erbB-2
immunoreactivity status in any given subset of tumours; i.e.
the presence of, or lack of expression of p53 protein and any
other combination of two receptor proteins could not be
utilised to predict tumour immunoreactivity with a third
receptor protein.
Clinicopathological associations
Tumour size was measured from the freshly resected patho-
logical specimen. One tumour was less than 1 cm in size and
was p53 positive (100%), 57 tumours were > 1 cm and
<2cm (18 p53 positive), 65 were >2cm and <3 cm (30
p53 positive), 19 were >3 cm and <4 cm (11 p53 positive),
and 4 were <5 cm in size (1 p53 positive).
Lymph node stage data was available on 137 patients. One
hundred and one of the tumours were lymph node Stage A
(axillary lymph node negative), 20 were Stage B (low axillary
lymph node tumour positive) and 16 Stage C (operable high
axillary lymph node positive). Of the Stage A tumours, 41
(40.6%) of cases were p53 po-sitive, of the Stage B tumours
eight (40.0%) of cases were p53 positive, and of the Stage C
tumours seven (43.7%) of the cases were p53 positive.
taining with pAb 1801, indicating p53 protein expression. x 60
The primary tumours of 17 of 31 (54.8%) patients with
distant tumour metastases showed p53 protein expression as
compared to 44 (38.3%) of the p53 positive primary tumours
in the subgroup of 115 patients without evidence of metas-
tatic disease. Twenty-six local recurrences of tumour were
identified and of these the primary tumour was p53 positive
in 12 cases (46.1%).
Statistical analysis
p53, EGFR, c-erbB-2, and oestrogen receptor
In an analysis of the 146 cases of invasive carcinoma examin-
ed, a statistically significant association of p53 protein ex-
pression and high tumour grade was found, x2= 14.1 (d.f. =
2), P<0.001 (see Table II). Using chi-square analysis a
highly statistically significant association of lack of tumour
p53 protein expression and positive tumour oestrogen recep-
tor protein status was identified, x2 = 19.78 (d.f. = 1), P<
0.001 (see Table III). An association of p53 protein expres-
sion and tumour EGFR expression; x2 = 7.07 (d.f. = 1), P<
0.01 and positive tumour c-erbB-2 status was also seen
X2 = 4.61 (d.f. = 1), P= 0.032 (see Table III).
Clinicopathological associations andpatient survival
There was a trend towards significance of p53 expression and
increased regional tumour recurrence in 143 patients on
whom recurrence data was available x2 = 3.20 (d.f. = 1),
Table II Tumour p53, EGFR and c-erbB-2 immunoreactivity and
tumour grade
Tumour p53 EGFR c-erbB-2
Grade POS/NEG POS/NEG POS/NEG
1 3/18 5/16 3/18
2 15/32 12/35 20/27
3 43/35 31/47 35/43
P<0.001 (S) P = 0.16 (NS) P = 0.035 (S)a
a(S) Statistically significant; (NS) Not statistically significant.
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Table III Tumour p53, EGFR, c-erbB-2 staining and oestrogen
receptor status
p53 Protein expression
POS NEG
EGFR pos 28 20
EGFR neg 33 65
X= 7.07 (d.f.= 1); P<0.01 (S)a
c-erbB-2 pos 31 27
c-erbB-2 neg 30 58
X2 = 4.61 (d.f. = 1); P = 0.032 (S)'
Oestrogen receptor pos 26 67
Oestrogen receptor neg 29 12
X2 = 19.78 (d.f. = 1); P<0.001 (S)a
a(S) statistically significant.
P = 0.074. There was no association between p53 protein
expression and primary tumour size x2 = 6.52 (d.f. = 4), P =
0.164, or lymph node stage (Stage A - lymph node negative,
Stage B and C - operable lymph node positive) x2 = 0.065
(d.f. = 2), P = 0.97 in the 137 patients on whom lymph node
stage data was available. There was also no association
between p53 protein expression and presence of distant meta-
stases x2 = 2.12 (d.f. = 1), P = 0.145, or local tumour recur-
rence x2 =0.067 (d.f. = 1), P= 0.795.
A non-significant trend towards significance of p53 expres-
sion and poorer patient survival was identified in the sub-
group of 61 patients with tumours showing p53 expression;
%2 = 3.76 (d.f. = 1), P = 0.053 (see Figure 2).
Discussion
In this study of 149 cases of primary symptomatic breast
carcinoma taken from the Nottingham/Tenovus Primary
Breast Carcinoma Series (146 invasive carcinomas and three
cases of DCIS) we have demonstrated a statistically signi-
ficant association between expression of the p53 protein and
high tumour grade, expression of EGFR, and c-erbB-2 pro-
tein overexpression. A strong negative association of p53
protein expression and positive tumour oestrogen receptor
status was also identified. A non-statistically significant trend
towards poorer survival was identified in the subgroup of 62
cases (42.5%) that showed p53 expression (see Figure 2).
Other groups have also found a similar association of p53
protein expression in breast carcinoma and high tumour
grade (poor tumour differentiation) (Cattoretti et al., 1988a;
Ostrowski et al., 1991; Walker et al., 1991) with a similar
trend towards poorer survival in patients with tumours ex-
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pressing the p53 protein noted in one other published series
(Ostrowski et al., 1991).
A statistically significant association of p53 and c-erbB-2
overexpression was identified. This association has not been
previously reported. Three other previous studies failed to
find an association between p53 protein expression and c-
erbB-2 overexpression (Davidoff et al., 1991b; Horak et al.,
1991; Walker et al., 1991). A significant association between
p53 and EGFR expression has been noted in two other
published series (Cattoretti et al., 1988; Horak et al., 1991).
Other authors have also reported a similar relationship of
p53 protein expression and negative tumour oestrogen recep-
tor status in breast carcinoma (Cattoretti et al., 1988a,b;
Davidoff et al., 1991b; Walker et al., 1991) although Horak
et al. were unable to confirm this finding (Horak et al., 1991).
The lack of association of p53 protein expression and pri-
mary breast tumour size has not been previously reported to
our knowledge.
From our data p53 protein expression does not appear to
be a specific feature of subtypes of invasive mammary car-
cinoma although special types of carcinoma were not present
in sufficient numbers to draw definite conclusions about exp-
ression of p53 in rarer types. Expression of p53 protein does
however appear to be rare in invasive lobular carcinomas of
classical type. This study has confirmed earlier findings in
other studies showing a relationship between p53 protein
expression and high tumour grade, EGFR expression and a
negative association with oestrogen receptor status. A non-
significant survival disadvantage was seen in patients with
tumours showing p53 protein expression as was also shown
in one other previous study. We have also identified a rela-
tionship between p53 protein expression and immunocyto-
chemical overexpression of the c-erbB-2 protein, a finding
which was not identified in three other published series.
Other published studies have not examined the relationship
between p53 and local tumour recurrence, regional recur-
rence, or presence of distant metastases. We have also shown
that expression of p53 protein is less common in the special
types of breast carcinoma such as tubular, tubular/mixed, or
lobular which tend to be of lower histological grade,
although insufficient numbers of special types of mammary
carcinoma were available for meaningful subgroup analysis
by tumour type.
The results of immunohistochemical analysis of the p53
gene protein in both our own and in other series have shown
that p53 protein expression in neoplastic cells is usually
nuclear, although some tumour cell cytoplasmic staining may
also be identifiable (Bartek et al., 1991; Cattoretti et al., 1988;
Iggo et al., 1990). Tumour cell p53 staining appears to be
associated with p53 gene mutation, at least in some cases
(Davidoff et al., 1991a; Iggo et al., 1990), as well as in breast
carcinoma cell lines (Bartek et al., 1990b), although altered
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Figure 2 Survival of patients by primary tumour p53 protein expression. The subgroup of patients with tumours showing p53
expression just fails to achieve statistical significance.
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p53 protein expression may also be related to altered and
abnormal p53 protein degradation in certain situations
(Wynford-Thomas, 1992).
The presence of p53 protein expression in some cases of
pure DCIS (one of three in our series) was also noted in
three other series (Bartek et al., 1990a; Davidoff et al., 1991a;
Walker et al., 1991). This finding supports the hypothesis
that p53 protein expression and by inference p53 gene muta-
tion is present in the early stages of human breast cancer.
Davidoff et al. showed that two of 15 cases of pure DCIS in
their series expressed high levels of p53 protein. Analysis of
the p53 mRNA from one of these two cases by polymerase
chain reaction demonstrated a p53 mRNA nucleotide substi-
tution, infering altered the amino-acid composition of p53
protein (Davidoff et al., 1991a). This implies that p53 gene
mutations may be present in the early stages of breast cancer.
Expression of the same mutant p53 mRNA was also identi-
fied in both the in situ and invasive components of the same
breast carcinoma, implying that p53 gene mutations may be
maintained in the progression of breast carcinoma from
DCIS to invasive disease.
If the hypothesis that p53 gene mutation is an early event
in breast carcinoma is correct it is not surprising that there is
no association between p53 protein expression and lymph
node tumour status, distant metastases, or local recurrence of
carcinoma. Other series have also observed a similar lack of
association of p53 protein expression and lymph node status
(Cattoretti et al., 1988; Ostrowski et al., 1991; Walker et al.,
1991) although an association of p53 expression and advanc-
ed lymph node status was reported by Davidoff et al.
(199lb). Our data showing a lack of association of p53
protein expression, presence of distant metastases and local
tumour recurrence would also be consistent with our finding
of a lack of association of p53 protein expression and breast
primary tumour lymph nodal status as described above.
p53 gene mutations are relatively common in invasive
breast carcinoma (Prosser et al., 1990; Thompson et al.,
1990) and have also been identified in breast carcinoma cell
lines (Bartek et al., 1990b). The wild type p53 gene has been
shown to act as a suppressor of cellular growth in human
breast carcinoma cells, as shown by a study of MDA-MB468
and T47D breast carcinoma cell lines which contain the
mutant p53 gene, but which then subsequently fail to grow
after DNA transfection with the wild type p53 gene (Casey et
al., 1991).
Recent evidence points to clonal expansion of mutant p53
gene containing cells in the progression of primary brain
tumours (Sidransky et al., 1992), implying that tumour cells
which show p53 gene mutations may have a selective growth
advantage as compared to tumour cells without p53 gene
mutations, as predicted by Nowell (1976). Expression of the
p53 gene protein appears to be a common event in human
breast cancer and expression is directly related to poor
tumour grade, epidermal growth factor receptor expression,
c-erbB-2 protein overexpression, and negative tumour oest-
rogen receptor protein status.
We were unable to show that p53 protein expression is an
independent prognostic factor for patient survival, although
a near significant tendency towards poorer survival was seen
in tumours that showed p53 protein expression. Our data
would be consistent with p53 protein expression, and by
inference p53 gene mutation or alteration in cellular p53
protein metabolism and degradation being an early event in
human breast cancer. The recent observation that clonal
expansion of mutant p53 containing tumour cell lineages
occurs in primary cerebral gliomas would offer an attractive
if incomplete explanation of our own findings if similar
clonal expansion were also to occur in mammary carcino-
genesis.
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